In our experimental resistant cell model, the mesenchymal-like and cancer stem properties were enhanced in therapeutic-resistant GBM cells, which was attributed to activated TGF-β signaling and facilitation of the activity of ALDHs. This evidence concerns the gene TGFB1 and glioblastoma.